Beware of This Iron Ore Stock
When the U.S. initiated a trade war through tariffs, it hurt global economic growth. After consumers spent more to avoid the tariff, that tailwind is gone. This will hurt demand for aluminum, steel, iron ore, and copper.Cleveland-Cliffs (CLF), whose stock lost 60% in the last year as of last week, is the riskiest iron ore producer. In the first quarter, Cliffs posted a $0.92 loss (non-GAAP). Revenue fell by 11% Y/Y to $4.63 billion. In fiscal year 2025, the firm is forecasting a steel unit cost cut of $50 per net ton. Capital expenditures will be $625 million, down from a previous target of $700 million.The 25% tariffs on steel will hurt sales. Unfortunately, its acquisition of Stelco increases the headwinds, along with hurting its balance sheet. CEO Goncalves said that the broader tariffs on Canada also had an impact on the company’s clients. Clients were impaired in selling their products to the U.S. markets.The CEO said he would not have been so eager to buy Stelco if he had known the U.S. would not treat Canada as its friend. Still, Goncalves said that the Carney-Trump meeting is a step in the right direction.Your TakeawayInvestors should expect iron ore markets to worsen before they get better. Short sellers hold a 14.14% short float against the stock.Consider watching Newmont (NEM) and Teck Resources (TECK) for gold mining exposure and Freeport-McMoRan for copper.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


